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Abstract
Background: Malaria carries high case fatality among children with sickle cell anaemia. In Uganda,
chloroquine is used for prophylaxis in these children despite unacceptably high levels of resistance.
Intermittent presumptive treatment with sulphadoxine-pyrimethamine  (SP) has shown great
potential for reducing prevalence of malaria and anaemia among pregnant women and infants.
Objective:  To compare the efficacy of monthly SP presumptive treatment, versus weekly
chloroquine for malaria prophylaxis in children attending the Sickle Cell Clinic, Mulago Hospital.
Methods: Two hundred and forty two children with sickle cell anaemia were randomized to
presumptive treatment with SP or weekly chloroquine for malaria prophylaxis. Active detection of
malaria was made at each weekly visit to the clinic over one month. The primary outcome measure
was the proportion of children with one malaria episode at one month follow-up. The secondary
outcome measures included malaria-related admissions and adverse effects of the drugs.
Results: Ninety-three percent (114/122) of the children in the chloroquine group and 94% (113/
120) in the SP group completed one month follow up. SP reduced prevalence of malaria by 50%
compared to chloroquine [OR = 0.50, (95% CI 0.26-0.97)]; p = 0.042. Six percent (7/122) of the
children receiving weekly chloroquine had malaria related admissions compared to 2.5% (3/120) on
presumptive treatment with SP. No serious drug effects were reported in both treatment groups
Conclusion: Presumptive treatment with SP was more efficacious than weekly chloroquine in
reducing prevalence of malaria in children with sickle cell anaemia. Continued use of chloroquine
for malaria chemoprophylaxis in children with sickle cell anaemia in Uganda does not seem to be
justified.
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Background
Sickle cell anaemia (SCA) is a major health problem in
Uganda with an average of 25,000 babies born annually
[1,2]. Eighty percent of these may die of malaria before
two years of age [3]. In Africa, an average of 200,000
babies are born with SCA annually and 50% die before
five years of age secondary to anaemia, pneumonia and
malaria [3,4].
Persons with SCA are four times more susceptible to
malaria than those with sickle cell trait. Malaria is a major
contributor to morbidity and mortality in these children
[3-7]. It precipitates both anaemia and painful crises and
increases the risk of death [4]. In Ghana painful crises
occurred frequently during high malaria transmission and
malaria accounted for 15.7% of the painful crises requir-
ing admission [8,9].
In Uganda, chloroquine chemoprophylaxis was first used
in 1962 where it significantly reduced malaria incidence
by 43% [7,10]. While chloroquine resistance was negligi-
ble then, in the recent past it has become unacceptably
high ranging from 60 to 80% [7,11,12]. Some recent stud-
ies show that chemoprophylaxis with chloroquine does
not appreciably reduce morbidity due to malaria in chil-
dren. For example, in Ethiopia, clinic visits for morbidity
due to malaria were not reduced by chemoprophylaxis
with chloroquine [13]. Another study from Uganda,
reported malaria parasitaemia in 44% of sicklers with
anaemic crises despite receiving weekly chloroquine[14].
Intermittent presumptive treatment is a new approach to
malaria prevention. This strategy was first used among
pregnant women among whom it was found to be very
effective. It has been successfully used in Tanzania, Ghana
and Mozambique among infants [15]. The most success-
ful drug for this strategy is sulphadoxine-pyrimethamine
(SP) despite reported resistance to this drug [16]. Hitherto
no study been has been carried out in Uganda to assess its
efficacy of chloroquine chemoprophylaxis, and yet it
remains standard of care for children with sickle cell anae-
mia. We carried out a double-blind randomized control-
led trial to compare the efficacy of weekly chloroquine
with monthly SP for malaria prevention in children with
sickle cell anaemia in order to inform policy on chloro-
quine use for chemoprophylaxis.
Methods
Patients
The study was carried out at the Sickle cell Clinic situated
in Mulago, Uganda's national referral hospital in Kam-
pala, from October 2006 to February 2007. Malaria trans-
mission in this area is mesoendemic and perennial but
peaks during the rainy seasons (from March - May, and
September - November) [17]. The annual inoculation rate
ranges from nine to 10 infective bites per year.
Children between six months and 12 years of age attend-
ing the sickle cell clinic were consecutively selected and
enrolled if they met the inclusion criteria, that is: 1) living
within 10 kilometers from the Hospital; 2) having a neg-
ative malaria smear; 3) parents or guardians consented to
participation. Children with a history of allergy to sul-
phonamides were excluded; those on co-trimoxazole
prophylaxis or those with any severe illnesses needing
admission. The study was approved by Makerere Univer-
sity Faculty of Medicine Ethics and Research Committee
and Uganda National Council for Science and Technol-
ogy.
Design
This was a double-blind randomized controlled trial,
where children between six months and 12 years of age
attending the sickle cell clinic were randomized to receive
either monthly SP or weekly chloroquine. The sample size
of 242 was based on the assumption that the prevalence
of malaria would 29.4% in the chloroquine group and
11.1% in the SP group [18,19] with an α = 0.05, a power
of 90% and an estimated 10% loss to follow.
Randomization and blinding
A paediatrician not involved in the study generated a set
of 242 random numbers. These numbers were then
assigned to two codes in blocks of 4 to 12. Each partici-
pant was assigned a serial enrolment number and a ran-
dom number corresponding to the treatment code. The
pills were packed in an opaque envelope labeled with
both the study serial number and a random number cor-
responding to the intervention. The drugs were packed in
envelopes and released to the study team only after an eli-
gible participant had been enrolled. The drugs and pla-
cebo were similar in colour and shape. They were
manufactured by the same company (Kampala Pharma-
ceutical Industries) and labeled using two codes. Each
(CQ) sugar coated tablet contained 150 mg chloroquine
base and SP tablet contained sulphadoxine 500 mg and
pyrimethamine 25 mg. The treatment code was concealed
to the study participants, the treatment nurse and the
investigators. The randomization code was only released
to the investigators following completion of data analysis.
Drug administration
The drug were administered by a treatment nurse accord-
ing to the body weight of the patients as follows: chloro-
quine 5 mg/kg and sulphadoxine(25 mg/kg)-
pyrimethamine (1.25 mg/kg). Participants were observed
for 30 minutes after drug administration and treatment re-
administered if vomiting occurred.Malaria Journal 2009, 8:237 http://www.malariajournal.com/content/8/1/237
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Follow up and outcomes
Patients were followed up weekly for one month. At each
visit, a finger prick for malaria parasites and parasite den-
sity estimation was done, in addition to haemoglobin
estimation by Drabkin's method. Parents were requested
to report any adverse events to the investigators. A malaria
episode was considered if the study participant had fever
documented by a temperature of ≥ 37.5°C and presence
of any Plasmodium falciparum parasite. Children who
developed malaria were treated according to the national
treatment guidelines at the time (artemether-lumefan-
trine for uncomplicated malaria, and quinine for severe
malaria).
Statistical analysis
Analysis was by intention to treat: that is all patients ran-
domized were analysed.
The occurrence of at least one episode of malaria in the
two treatment groups was compared using Odds Ratios
and 95% confidence interval. The student's t-test was used
for continuous variables. Logistic regression analysis was
used to predict variables affecting the occurrence of
malaria.
Results
Trial profile (Figure 1)
During this period 278 patients were screened and 36
patients did not fulfill the inclusion criteria. Two hundred
and forty two were randomized to either SP (monthly) or
chloroquine weekly (120 and 122 respectively). Seven
patients were lost to follow up from the SP arm and 8
from the CQ arm. All these patients were lost follow up
during the first week after enrollment. Five patients from
each group that were lost to follow-up relocated to other
Trial profile Figure 1
Trial profile.
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places during the study period. The rest had different rea-
sons such as a guardian's busy work schedule or having a
sick guardian. Two hundred and twenty seven patients
were followed up for one month (113 SP arm and 114 CQ
arm). Baseline and laboratory characteristics (Table 1)
were similar in both treatment groups implying successful
randomization.
Treatment outcome
Proportion of children with malaria
Only 14% (17/120) of the children in the SP arm con-
tracted malaria compared to 24.6% (30/122) in the CQ
arm by one month follow-up. Children receiving chloro-
quine were almost two times more likely to have malaria
compared with those receiving SP (Odd's Ratio 1.98 95%
CI 1.023 - 3.82).
Malaria-related admissions
A higher proportion of children had malaria related
admissions in the CQ arm, compared to those in the SP
arm (5.7% versus 2.5%). Children receiving chloroquine
were almost two and half times more likely to be admitted
than those receiving SP. (OR = 2.4, 95% CI 0.6 - 10.0)
though this was not statistically significant, p = 0.223.
All cause admissions
Reasons for admissions were as follows; SP group: malaria
(2), malaria and anaemia (1), anaemia (2) septicaemia
and anaemia (1). Chloroquine group: lobar pneumonia
(1), malaria and anaemia (2), septicaemia (3), malaria
with painful crisis (3), and malaria (2). Even though there
were more all cause admissions in the chloroquine group
Table 1: Baseline characteristics of patients in both treatment arms at the time of enrollment
Variable Treatment SP
N = 120
Treatment CQ
N = 122
Odds ratio 95% CI P- Value
Fever
Yes
No
26 (21.7%)
94 (78.3%)
24 (19.7%)
98 (80.3%)
1.129 0.06- 2.105 0.07
Joint pains
Yes
No
40 (38.3%)
80 (73.3%)
49 (40.2%)
73 (59.8%)
0.745 0.441-1.259 0.27
Headache
Yes
No
11 (9.2%)
109 (90.8%)
13 (10.7%)
109 (89.3%)
0.846 0.363-1.971 0.69
Drugs for malaria prophylaxis before the study
Yes
No
99 (48.3%)
21(56.8%)
106 (51.7%)
16 (43.2%)
0.712 0.351-1.441 0.89
Bed net use
Yes
No
77 (64.2%)
43 (35.8%)
98 (80.3%)
24 (19.7%)
0.44 0.23 -0.82 0.05
Pallor
Yes
No
115 (95.8%)
5 (4.2%)
115 (94.3%)
7 (5.7%)
1.4 0.432- 4.540 0.57
Jaundice
Yes
No
110 (91.7%)
10 (90.2%)
110 (90.2%)
12 (9.8%)
1.2 0.49 - 2.893 0.68
Age (yrs) mean (SD)
Age < 5 yrs
Age > 5 yrs
5.49 (4.5)
67 (55.8%)
53 (44.2%)
5.5 (4.3)
60 (49.2%)
62 (50.8%)
N/A
...
N/A
....
N/A
....
N/A
...
N/A
...
N/A
...
0.89
0.30
Sex
Female
Male
66(55%)
54(45.0%)
55(45.1%)
67(54.9%)
N/A
...
N/A
...
N/A
...
N/A
...
0.01*
Weight (kg) 18.43 ± 7.7 18.10 ± 6.8 N/A
...
N/A
...
0.72
Pulse (per min.) 92 ± 13.8 93 ± 15.0 N/A
...
N/A
...
0.58
Temperature(°C) 36.79 ± 2.0 36.5 ± 2.1 N/A
...
N/A
...
0.63
Haemoglobin (g/dl) 7.3 ± 1.29 7.2 ± 1.25 N/A
...
N/A
...
0.45
* Values are numbers, percentage unless other wise stated; N/A - Not applicableMalaria Journal 2009, 8:237 http://www.malariajournal.com/content/8/1/237
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(11/122) 9% than in the SP group (6/120) 5%, the differ-
ence was not statistically significant (p = 0.22)
Drug side effects
Side effects were assessed for on a weekly basis as children
actively reported to the clinic. The proportion of children
that vomited after administration of the drugs was 6.6%
(SP) versus 11.5% (CQ arm. Pruritus was reported in
1.6% of the children in the SP arm versus 1.8% in the CQ
arm. Finally blurring of vision was almost similar in both
arms (1.6%% CQ versus 0.8% SP). None of the skin
rashes documented were suggestive of a drug reaction. No
serious adverse drug reactions were reported in any of the
treatment arms (Table 2).
Discussion
Children with at least one malaria episode by one month
Children receiving weekly chloroquine were two times
more likely to get malaria compared to those on SP. This
shows that SP was more protective, reducing the preva-
lence of malaria by 50% compared to chloroquine. This
difference in efficacy between the two drugs could be
explained by the fact that resistance to therapeutic treat-
ment of chloroquine (60%-80%) is higher compared to
SP (18% - 25%) in Uganda [12,20].
The other reason is that SP has a longer half life and its ter-
minal elimination phase normally exceeds the minimum
parasiticidal concentrations (lowest concentrations that
give maximum effect). In contrast this does not occur for
chloroquine [21].
While SP may have failed as a treatment drug it is still
effective for prophylaxis [22]. Several studies from Ghana,
Mozambique and Tanzania have documented its useful-
ness in prophylaxis and particularly in reducing malaria
episodes even in areas where resistance is high [16,22].
In the current study, 24.6% of children receiving chloro-
quine contracted at least one episode of malaria com-
pared to 40% reported in the Ethiopian study [13]. This is
probably due to a relatively lower resistance to chloro-
quine therapeutic treatment reported in Uganda than that
reported from Ethiopia [23,24].
Malaria-related admissions
In our study, SP reduced malaria related admissions by
50% compared to chloroquine, but this was not statisti-
cally significant. This suggests that SP may have a role in
reducing malaria related admissions. This is in contrast to
results from Ghana, where the reduction in malaria
related admissions by SP was 39% in comparison to pla-
cebo among children without sickle anaemia[20].
All cause admissions
Although all cause admissions varied, the percentage of
admissions was higher in the chloroquine group (9% ver-
sus 5%). Of note, admissions due to lobar pneumonia
(1), painful crisis (3) only occurred in those receiving
chloroquine. This might be because sulphonamides may
offer an anti-bacterial effect against the diseases as has
been reported among children with HIV infection [25].
This implies that SP may reduce morbidity from other
causes compared with chloroquine. Nonetheless, the
reduction in the admissions was not statistically signifi-
cant and defers from findings reported from Tanzania,
and Nigeria [15,26].
Side-effects
Drug side-effects such as vomiting, skin rash, pruritus,
blurred vision were documented in a small proportion of
the children (range 0.8% to 11.5%) [15,20]. No serious
adverse effects were reported in the two treatment arms
and this is consistent with findings in other studies from
Tanzania, Mozambique and Ghana [16,22].
Conclusion
Monthly presumptive treatment with SP was more effica-
cious than weekly chloroquine in reducing prevalence of
malaria among children with sickle cell anaemia. Minor
Table 2: Side effects documented in both treatment groups over one month follow up
Symptom Treatment SP
N = 120
Treatment CQ
N = 122
Odd's ratio 95% C1 P Value
Vomiting
Yes
No
8 (6.6%)
112 (93.4%)
14(11.5%)
108(88.5%)
0.55 0.12 - 1.36 0.20
Blurred vision
Yes
No
2 (1.6%)
118(98.4%)
1(0.8%)
121 (99.2%)
1.6 0.08 - 6.2 0.66
Pruritus
Yes
No
2(1.6%)
118(98.4%)
3(1.8%)
119(98.2%)
0.6 0.07 - 4.67 0.32
Skin rash
Yes
No
5 (4.1%)
115 (95.9%)
3 (1.8%)
119 (98.2%)
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side effects such as pruritus, vomiting, blurred vision and
skin rash were reported in a small proportion of patients
while no serious adverse events wee documented.
Monthly SP should be considered for malaria prophylaxis
in children with sickle cell anaemia. Continued use of
chloroquine for malaria chemoprophylaxis in children
with sickle cell anaemia in Uganda does not seem to be
justified.
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